Identifying dosage-sensitive genes is a key to understand the mechanisms underlying intellectual disability in Down syndrome (DS). The Dp(17Abcg1-Cbs)1Yah DS mouse model (Dp1Yah) shows cognitive phenotypes that need to be investigated to identify the main genetic driver. Here, we report that three copies of the cystathionine-beta-synthase gene (Cbs) in the Dp1Yah mice are necessary to observe a deficit in the novel object recognition (NOR) paradigm. Moreover, the overexpression of Cbs alone is sufficient to induce deficits in the NOR test. Accordingly, overexpressing human CBS specifically in Camk2a-expressing neurons leads to impaired objects discrimination. Altogether, this shows that Cbs overdosage is involved in DS learning and memory phenotypes. To go further, we identified compounds that interfere with the phenotypical consequence of CBS overdosage in yeast. Pharmacological intervention in Tg(CBS) mice with one selected compound restored memory in the NOR test. In addition, using a genetic approach, we demonstrated an epistatic interaction between Cbs and Dyrk1a, another human chromosome 21-located gene (which encodes the dual-specificity tyrosine phosphorylation-regulated kinase 1a) and an already known target for DS therapeutic intervention. Further analysis using proteomic approaches highlighted several molecular pathways, including synaptic transmission,
cell projection morphogenesis and actin cytoskeleton, that are affected by DYRK1A and CBS overexpression. Overall, we demonstrated that CBS overdosage underpins the DS-related recognition memory deficit and that both CBS and DYRK1A interact to control accurate memory processes in DS. In addition, our study establishes CBS as an intervention point for treating intellectual deficiencies linked to DS.
Introduction
Down Syndrome (DS) is the most common aneuploidy observed in human. The presence of an extra copy of the human chromosome 21 (Hsa21, Hsa for Homo sapiens) is associated with intellectual disabilities and several specific morphological and physiological features. Phenotypic mapping in human bearing partial duplication highlighted the contribution of several regions of the Hsa21 to DS features (1, 2) . Additional information was collected from trisomic and monosomic mouse models to detect genomic regions sensitive to dosage and able to induce impairments in behaviour and other DSrelated traits (3) (4) (5) (6) (7) (8) (9) (10) (11) . Most of the efforts focused on the region homologous to the Hsa21 located on mouse chromosome 16 (Mmu16, Mmu for Mus musculus), highlighting the contribution of overdosage of the amyloid precursor protein (12) , the glutamate receptor, ionotropic, kainate 1 (Grik1) or the dual-specificity tyrosine phosphorylation-regulated kinase 1a (Dyrk1a) (13, 14) to DS cognitive defects. DYRK1A is currently the main target for therapeutic intervention with the identification of a few compounds inhibiting its kinase activity and improving mainly cognition in DS mouse models (15) (16) (17) (18) (19) (20) . However, models carrying trisomy of the region of Mmu17 homologous to the Hsa21 also showed learning and memory defects (21, 22) and appeared to have a major impact on DS phenotypes in mouse models (23) . The Dp(17Abcg1-Cbs)1Yah (called here Dp1Yah) mice are trisomic for 12 protein-encoding genes including three members of the trefoil factor families (Tff1-3), Tmprss3, Ubash3a, Rsph1, Slc37a1, Pknox1, Pde9a, Ndufv3, Wdr4 and Cbs. The region also encompasses six non-coding genes: Gm25447 (rRNA), Gm15318 (antisense lncRNA), Gm8437 (unclassified), Gm9902 (unclassified), 4833413E03Rik (lincRNA) and Gm24970 (miRNA). The Dp1Yah mice are defective in the novel object recognition (NOR) test and show long-lasting in vivo long-term potentiation (LTP) in the hippocampus while the corresponding monosomy in Ms2Yah mice (in which Abcg1 and U2af1 are deleted), induces defects in social discrimination with increased in vivo LTP (24) .
Interestingly, as observed in the rotarod test, the locomotor phenotype of the Tc1 transchromosomic mouse model carrying an almost complete Hsa21 is rescued when the Abcg1-Cbs region is returned to two copies in Tc1/Ms2Yah mice (25) . Similarly, the trisomy of a larger overlapping segment on Mmu17 from Abcg1 to Rrp1b induces an increased LTP as compared with controls in the Dp(17)Yey model (22) and was shown to genetically interact with the trisomy of the Lipi-Zbtb21 interval. More specifically, the trisomy of both the Abcg1-Rrp1b region and the Cbr1-Fam3b region was detrimental for learning and memory in the Morris water maze and for LTP in DS mouse models (23) .
Among the 11 trisomic genes in the Dp1Yah model, the Cbs, encodes a pyridoxal phosphate-dependent enzyme converting homocysteine to cystathionine. This first step of the transsulfuration pathway removes homocysteine from the methionine cycle thereby also affecting the folate and the methylation pathways, while contributing to the cysteine cycle. Of note, in human, homozygous loss-of-function mutations in CBS are associated with homocystinuria (OMIN236200), a metabolic condition with intellectual disability. CBS is also the major enzyme catalysing the production of H 2 S from L-cysteine (26) or from the condensation of homocysteine with cysteine (27) . H 2 S is now considered a major gasotransmitter in the brain (28) and interferes with synaptic transmission. Considering the up-regulated expression of CBS in several brain regions of the Dp1Yah model and its impact on intellectual disability, we decided to focus on Cbs and decipher the role of CBS in DS cognitive phenotypes. To this end, we generated and characterized constitutive and conditional changes in Cbs dosage in the nervous system of various mouse models. In addition, we identified pharmacological drugs able to counteract the phenotypical consequence of CBS overexpression, in particular behavioural impairments, and finally further analysed molecular changes induced by Cbs overdosage to understand the mechanisms perturbed in DS models. relative with the protection of animals used in scientific experimentation. YH was granted the accreditation 67-369 to perform the reported experiments in the animal facility (Agreement C67-218-40). For all these tests, mice were kept in specific pathogenfree conditions with free access to food and water. The light cycle was controlled as 12 h light and 12 h dark (lights on at 7 AM). All the behavioural tests were performed between 9:00 AM and 4:00 PM. Several mouse lines were used to decipher the influence of Cbs dosage changes: the trisomic mouse model, Dp(17Abcg1-Cbs)1Yah, named here Dp1Yah, carries a segmental duplication of the Abcg1-Cbs region of the Mmu17 (21) kept on the C57BL/6 J genetic background with continuous backcross during all the study (N > 7 generations); the inactivated allele of C57BL/6 J.Cbs tm1Unc (29) ; and the PAC transgenic line Tg(CBS)11181Eri [named here Tg(CBS)], originally identified as 60.4P102D1 (30) and backcrossed on C57BL/6J for more than seven generations. We designed, generated and selected the transgenic mouse line Tg(Prp-gfp-CBS)95-157ICS, named here Tg(Prp-gfp-CBS), to overexpress the human CBS cDNA from the murine prion promoter region (containing a 8477 bp region upstream of the ATG of the murine prion gene, i.e. 6170 bp promoter region, exon 1, intron 1 and beginning of exon 2) after the excision of a loxP-gfp-loxP interrupting cassette (Fig. 3A) . The transgenic mouse line was generated on the C57BL/6N genetic background. We used the transgenic Tg(Camk2a-cre)4Gsc mouse line (31), named here Tg(Camk2a-cre), as a glutamatergic neuron-specific Cre driver. The line was further bred on C57BL/6J for more than seven generations. When the Tg(Camk2-Cre)/0 × Tg(Prp-gfp-CBS)/0 cross was done, the genetic background of the cohorts was estimated to be around C57BL6 J(57%)/N(43%). The Dyrk1a BAC transgenic mouse line, named here Tg(Dyrk1a), was previously generated in our laboratory (32, 33) and their study was performed on animals with more than seven generations of backcross on the C57BL/6J genetic background. The cohorts for the Tg(Dyrk1a) and Dp1Yah were produced on the B6J genetic background (estimated at 98.8%). Genotype identification was performed on genomic DNA isolated from tail biopsies with specific PCR (Supplementary Material, Table S1 ).
Materials and Methods

Ethics statement, mouse lines and genotyping
Behavioural analysis
The number of animals required for behavioural analysis was estimated according to similar experiments we previously performed in DS mouse models (5, 21, 25) . All the mice used in the study were males and the controls were littermates. To investigate the role of Cbs in the Dp1Yah cognitive phenotypes, we generated two independent cohorts [cohort 1 (C1): wildtype (wt) littermates n = 11; Cbs tm1Unc/+ , n = 8; Dp1Yah, n = 8; Wt littermates (n = 13) and Tg(CBS)/0 (n = 17) hemizygotes were tested for circadian actimetry (14 weeks), Y-Maze (16 weeks), open field (17 weeks) and NOR (17 weeks). We added an additional group of wt (n = 9) and Tg(CBS)/0 (n = 10) to validate the results obtained in the NOR test for which animals were tested at the same age (17 weeks). A cohort with four genotypes [wt (n = 13), Tg(Camk2-Cre)/0 (n = 11), Tg(Prp-gfp-CBS)/0 (n = 12) and Tg(Camk2-Cre)/0, Tg(Prp-gfp-CBS)/0 (n = 14)] was evaluated through the same behavioural tests: rotarod (14 weeks), Y-maze (16 weeks) , open field (19-20 weeks) and NOR (19-20 weeks) . A total of 14 wt, 15 Tg(Dyrk1a), 13 Dp1Yah and 13 Dp1Yah/Tg(Dyrk1a) mutant mice were evaluated for the open field exploration (11-12 weeks), NOR test (11-12 weeks) and Y-maze (13 weeks). A second independent cohort with 11 wt, 10 Tg(Dyrk1a), 14 Dp1Yah and 10 Dp1Yah/Tg(Dyrk1a) was used for the Morris water maze learning test (14-16 weeks). The behavioural protocols for open-field, Y-maze and NOR, rotarod, water maze were detailed in the Supplementary information.
Drug screening in yeast
All plasmids were generated using standard procedures. Restriction enzymes and Taq polymerase were obtained from New England Biolabs (Evry, France). T4 DNA ligase was purchased from Promega and purified synthetic oligonucleotides from Eurogentec. Routine plasmid maintenance was carried out in DH5α and TOP10 bacteria strains. Yeast cystathionine bsynthase (Cys4) coding sequence was amplified from the genomic DNA of the W303 WT strain (see genotype below) using Bam-Cys4-F: CGGGATCCCGATGACTAAATCTGAGCAGCAAG and Xho-Cys4-R: GCCTCGAGTCTTATGCTAAGTAGCTCAGTAAATCC (that introduced BamHI and Xho1 restriction sites) and subcloned in the high copy number 2 μ-derived vectors p424-GPD and p426-GPD, each time under the control of the strong constitutive GDP promoter (34) . Transformation of yeast cells was performed using a standard lithium acetate method (35) .
The 
Mouse model treatment with disulfiram
A pre-clinical protocol was designed to target cognitive defects correlated to CBS overexpression in Tg(CBS) mice brain (Fig. 4D) . The selected molecule was DSF, a potent inhibitor of mitochondrial aldehyde dehydrogenase (ALDH) used for the treatment of chronic alcoholism. We based our experiment on the work of Kim et al. (36) in which the DSF effect on ethanol sensitization in mice was demonstrated. Behavioural studies were conducted in 12-16 week-old animals; to do so, we generated three independent cohorts, in which we tested four conditions taking into account the dose of DSF (or vehicle alone) and the genotype. For the cohorts (C1-C3), we produced respectively 5,7,3 (n = 15 in total) wt mice treated with vehicle, 5,3,6 (n = 14 in total) transgenic mice for human CBS [Tg(CBS)] treated with vehicle, 7,5,3 (n = 15 in total) wt mice treated with 10 mg/kg/day of DSF, 6,6,8 (n = 20 in total) Tg(CBS) mice treated with 10 mg/kg/day of DSF based on the dose previously administrated in the reference publication (37) . The local ethics committee, Com'Eth (n • 17), approved the mouse experimental procedures, under the accreditation number APAFIS#1564-2015083114276031 with YH as the principal investigator in this study. All assessments were scored blind to genotype and animals were randomly distributed to experimental groups and treatment as recommended by the ARRIVE guidelines (37, 38 
Quantitative proteomic analysis
We collected five hippocampi of littermates of the four genotypes: wt, Dp1Yah, Tg(Dyrk1a)/0 and [Dp1Yah,Tg(Dyrk1a)/0] after their behavioural evaluation at the age of 25-27 weeks. Samples were reduced, alkylated and digested with LysC and trypsin at 37 • C overnight. Five sets of samples with one sample from each genotype (four in total) were labelled with Thermo Scientific Tandem Mass isobaric tag (TMT), pooled and then analysed using an Ultimate 3000 nano-RSLC (Thermo Scientific, San Jose California) coupled in line with an Orbitrap ELITE (Thermo Scientific, San Jose California). An additional set was done comparing all the wt controls together. Briefly, peptides were separated on a C18 nano-column with a linear gradient of acetonitrile and analysed in a top 15 higher collision dissociation datadependent mass spectrometry. Data were processed by database searching using SequestHT (Thermo Fisher Scientific) with Proteome Discoverer 1.4 software (Thermo Fisher Scientific) against a mouse Swissprot database. Precursor and fragment mass tolerance were set at 7 and 20 ppm, respectively. Trypsin was set as an enzyme and up to two missed cleavages were allowed. Oxidation (M) and TMT-labelled peptides in primary amino groups (+229.163 Da K and N-ter) were set as variable modification and carbamidomethylation (C) as a fixed modification. We then compared our five wt samples to determine the sample closer to average score from the group and defined it as the reference sample. All the protein quantification was performed based on the reference wt sample. In total, we detected 1655 proteins filtered with false discovery rate at 5% with a minimum of two peptides for a given protein detected per genotypes. We calculated the mean of the fold change for each protein from all the samples [Dp1Yah, Tg(Dyrk1a) and Dp1Yah/Tg(Dyrk1a)] compared to control. From the preliminary data, we selected 208 proteins with variability levels below 40% and a fold change below 0.8 or above 1.2.
Western blot analysis
Ten micrograms of total proteins from cortex extracts were electrophoretically separated in SDS-polyacrylamide gels (10%) and then transferred to nitrocellulose membrane (120 V) during 1 h 30 min. Non-specific binding sites were blocked with 5% skim milk powder in tween-tris-buffer saline (TTBS) 1 h at room temperature. Immunoblotting was carried out with primary antibody (Supplementary Material, Table S3 ) incubated overnight at 4
• C. The next day, we started with three washing baths with TTBS, followed by secondary conjugated with horseradish peroxidase. The immunoreactions were visualized by ECL chemiluminescence system (Clarity TM western ECL substrate, Bio-Rad);
epifluorescence was captured with Amersham TM Imager 600.
Bands were detected at 18, 25 and 75 kDa, respectively for alphasynuclein (SNCA), synaptosomal-associated protein 25 (SNAP25) and fused in sarcoma (FUS) and signals were quantified with ImageJ.
Results
Three copies of Cbs are necessary to induce cognitive impairments in the Dp1Yah mice
To challenge the hypothesis that three copies of Cbs are necessary to induce behavioural deficits in the Dp1Yah mice, we combined the Dp1Yah mice with the Cbs tm1Unc/+ knock-out model ( Then we tested object memory. No difference was observed during the exploration of the familiar object in the presentation phase of the test (Fig. 1D, top left panel) . However, during the discrimination phase, after 1 h of retention, the Dp1Yah mutant mice were not able to differentiate the novel object from the familiar one (Fo) whereas the wt, Cbs tm1Unc/+ and the Overall this set of experiments demonstrated that three copies of Cbs are necessary to induce the Dp1Yah phenotypes in the NOR test. In addition, rescuing Cbs dosage induced a slight hyperactive phenotype during the exploration of a new environment and restored performance in the rotarod activity. Interestingly, returning back to wt level of expression of Cbs in the Abcg1-Cbs region enables another trisomic gene from this region to impact on the locomotor activity during exploratory behaviour of the mouse.
Dp1Yah/Cbs
The sole overexpression of a human CBS transgene impacts object recognition and locomotor activity
We used the Tg(CBS) model, a PAC transgenic line encompassing a 60 kb fragment with the human CBS locus (30) , to analyse the impact of the sole increase of Cbs dosage on behaviour and cognition. As shown in Figure 2A . Consequently, we demonstrated that CBS overexpression is sufficient to induce a deficit in the NOR memory and decreased locomotor activity during the dark phase while having no effect during the light phase.
Cbs overexpression in hippocampal and cortical neurons induces behavioural defects similar to Dp1Yah
We then checked if we could induce the cognitive deficits observed in DS mouse models by overexpressing Cbs in the hippocampal and cortical neurons, brain parts involved in learning and memory. Hence, we engineered the Tg(Prp-gfp-CBS) mouse strain in which the human CBS cDNA can be expressed from the prion promoter after the excision of the gfp cassette flanked by loxP sites (Fig. 3A) and selected one Tg(Prp-gfp-CBS) line with a pattern of expression in the anterior part of the adult brain (Fig. 3B) . We chose the Tg(Camk2a-cre) (31) , to direct the Cre expression in cortical and hippocampal glutamatergic neurons and we verified the expression of the human CBS in different brain regions of the double transgenic [Tg(Prp-gfp-CBS)/0, Tg(Camk2a-cre)/0]. As expected, we found expression levels comparable to the endogenous murine Cbs gene in cerebellum while human CBS was overexpressed in the hippocampus and the cortex (Fig. 3C) . Littermate wt animals, carrying the two single transgenic constructs and the two transgenes were produced and tested for object recognition. During the test, the control groups, namely wt, Tg Hence, overexpression of CBS is necessary and sufficient to induce object memory defect in a 1 h retention test with limited impact on other phenotypes. As such, CBS is a new gene that overdosage alters cognition in DS mouse models and as a consequence is likely to contribute to DS phenotypes. However, increased activity was observed during home cage monitoring over a light-dark-light cycle (B) with an increase in the distance travelled (C). In the Y-maze (E), Tg(CBS)/0 animals displayed altered SA with no change in the number of arm entries (D). In the NOR test (F), Tg(CBS)/0 mice displayed similar exploration activity compared to wt littermates but they did not discriminate the novel versus the familiar object when looking at the discrimination index (G) and the percentage of exploration time for both objects (H). (Values represent means + S.E.M. * P < 0.05, * * P < 0.01, * * * P < 0.001).
Identification of drugs that suppress the effects of Cys4/CBS overexpression both in yeast and mouse
A few studies have reported the identification of CBS inhibitors (39-44) but most of them were based on in vitro assays using a recombinant CBS enzyme as a drug target and led to the isolation of inhibitors with relatively low potency and limited selectivity, hence leading to the idea that CBS may be an undruggable enzyme. Therefore, we oriented toward an in cellulo phenotypebased assay that would allow the identification of drugs that interfere with the phenotypical consequences of CBS overexpression and thereby that do not necessarily directly target the CBS enzyme. The budding yeast Saccharomyces cerevisiae contains a functional homolog of CBS and has been shown to be a relevant system to model pathophysiological mechanisms involved in a number of human disorders and to perform chemobiological approaches that aim at identifying both drugs and new therapeutic targets (45) (46) (47) (48) (49) (50) (51) . We thus decided to create a yeast model in which the phenotypical consequences of CBS overexpression may be easily and conveniently monitored in order to get potential in cellulo high throughput drug screening procedure. We reasoned that if we overexpressed CBS at a sufficient level, this should lead to a decreased intracellular level of methionine, similarly to what was shown in patients, and therefore that yeast cells would become methionine auxotroph and thereby unable to grow on methionine-free minimal media. As the human CBS protein is not very stable in yeast cells and therefore cannot be expressed at high levels (52), we decided to overexpress Cys4p, the CBS homolog in S. cerevisiae. Cys4p presents the same domains and domain organization as CBS apart from the N-terminal heme-binding domain that is absent in the yeast protein (53) . To get a degree of methionine auxotrophy sufficient to allow an efficient screening, we expressed Cys4 from the strong constitutive GPD promoter from two different high copy number 2 μ vectors (each present at ∼50 copies per cell) and supplemented the growth medium with serine, which is one of the Cys4p/CBS substrates that could otherwise become limiting upon Cys4 overexpression (Fig. 4A) .
Using this model, we tested ≈ 2200 compounds from three different chemical libraries consisting mainly of repurposed drugs for their ability to suppress the methionine auxotrophy induced by Cys4p overexpression. We exploited a similar principle as a yeast-based screening setup previously (46, 47, 49, 54) . Briefly, we spread yeast cells overexpressing Cys4 on a solid agar-based methionine-free minimal medium. Then we put filters on the agar surface and add different drugs from chemical libraries on each filter. After 3 days of incubation at 33
• C, active compounds were identified by a halo of restored/enhanced growth around the filter on which they were loaded (Fig. 4B) . The advantage of this method is that it allows in one simple experiment numerous compounds to be tested across a large range of concentrations due to the diffusion of the molecule in the medium surrounding the filter onto which it was deposited. This design drastically improves the sensitivity of the screen because the screened compounds can be toxic at high concentrations whereas being active at subtoxic concentrations. We identified four different compounds, among which DSF (Fig. 4C ). Next, we tested if DSF was able to restore the object recognition in the mouse model overexpressing human CBS. Three independent cohorts of Tg(CBS) and control littermates were treated with DSF (10 mg/kg/day) for 10 days before being tested for the NOR. As shown in Figure 4D , DSF-treated transgenic animals were restored in the NOR paradigm whereas non-treated mutant animals were still not able to discriminate the No versus the Fo. Interestingly, the wt-treated individuals were no more able to perform the discrimination while the vehicle-treated controls were able to do so [Student-paired t-test: vehicle-treated wt «No versus Fo» P = 0.006, DSF-treated wt «No versus Fo» P = 0.11 and vehicle-treated Tg(CBS) «No versus Fo» P = 0.59, DSF-treated Tg(CBS) «No versus Fo» P = 0.05]. Altogether, these results confirm DMSO was used as a negative control and added to the upper right filter and methionine, the positive control, was loaded on the bottom left filter (B). At the remaining positions, individual compounds from the chemical libraries were added and plates were incubated for 3 days at 33 • C. Three types of growth profiles can be observed around the filters where the compounds were loaded. Either the compounds have no effect, which results in the same basal growth (indeed, the overexpression of Cys4 does not lead to a complete methionine auxotrophy as evidenced in C), or it is toxic, which results in a total absence of growth (visualized as a dark halo corresponding to the colour of the solid media). The last possibility corresponds to active drugs that suppress the methionine auxotrophy, thereby leading to a halo of enhanced growth around the filter. Of note, a single compound can display various effects (which is the case for DSF, see below), it can be toxic at high concentration (immediately around the filter), thereby leading to a halo of non-growing cells at the immediate vicinity of the filter and then become active at sub-toxic concentrations that leads to a crown of cells growing at a faster rate (leading to the formation of bigger colonies) and then become inactive at sub-active concentrations (at a bigger distance from the filter). The dose-dependent effect of DSF on Cys4-overexpressing cells is shown, and its molecular structure is depicted (C). To test DSF in mice, treatment was done on Tg(CBS) cohort starting at D1 and ending at D10 (D). Each group received a daily dose of 10 mg/kg/day of DSF for 10 days followed by an open field paradigm (D10) with the object recognition test performed on D11 (with 1 h of retention time). The graph at the bottom showed the percentage of time spent on the novel versus the familiar object during the tests. The vehicule-treated wt mice were able to discriminate both objects as the DSF-treated Tg(CBS) animals. On the contrary, non-treated transgenic animals were not able to do so and the DSF-treated wt animals were impaired in the test confirming that the drug affects the consequences of CBS activity in vivo (values represent means + S.E.M. * P < 0.05, * * P < 0.01, * * * P < 0.001).
that the phenotypical consequences of the overexpression of CBS could be targeted by drugs to restore some of the cognitive performance altered in DS models. They also emphasize that the inhibition of CBS, direct or indirect, should be mild and only partial as a strong inhibition may be detrimental as illustrated by the cognitive dysfunction observed in homocystinuria.
Epistatic interaction between Dyrk1a and the Abcg1-Cbs region drives recognition memory in DS mouse models
Dyrk1a is a major driver gene of DS cognitive defects (55) and a decrease in Cbs dosage is known to change the expression of Dyrk1a in the brain and other organs (56) (57) (58) . Thus in order to test the functional interaction of Cbs and Dyrk1a overdosage, we combined the Dp1Yah with the Tg(Dyrk1a) mouse model, with Dyrk1a mRNA expression ratio around 1.5 compared with control littermate (32) and the overexpression of the protein and its kinase activity (33) . Tg(Dyrk1a) mice present increased spontaneous activity compared with wt in the open field test. This hyperactivity was also observed in the double transgenic Dp1Yah/Tg(Dyrk1a) while it was absent from Dp1Yah animals [ Fig. 5A , Student t-test wt versus Dp1Yah P = 0.460, wt versus Tg(Dyrk1a) P = 0.002 and wt versus Dp1Yah/Tg(Dyrk1a) P = 0.006, Tg(Dyrk1a) versus Dp1Yah/Tg(Dyrk1a) P = 0.200]. Hyperactivity was confirmed in the Y-maze, with both Tg(Dyrk1a) and Dp1Yah/Tg(Dyrk1a) performing more arms visits than the controls and Dp1Yah mice [ Fig. 5B , Student t-test wt versus Dp1Yah P = 0.800, wt versus Tg(Dyrk1a) P = 0.005 and wt versus Dp1Yah/Tg(Dyrk1a) P = 0.005, Tg(Dyrk1a) versus Dp1Yah/Tg(Dyrk1a) P = 0.881]. The working memory defect observed in the Y-maze for Tg(Dyrk1a) mice was not rescued in Dp1Yah/Tg(Dyrk1a) double transgenic mice [ Fig. 5B , oneway ANOVA F(3, 48) = 4.14 P = 0.011, post hoc Tukey method wt versus Tg(Dyrk1a) P = 0.042, wt versus Dp1Yah/Tg(Dyrk1a) P = 0.019 and Tg(Dyrk1a) versus Dp1Yah/Tg(Dyrk1a) P = 0.203]. Then, we tested the NOR memory after 1 h of retention (Fig. 5C ). As expected, the two single mutants were impaired [two ways ANOVA, variables 'genotype' and 'objects': F(3, 70) = 7.09 with P < 0.001, post hoc Tukey test: Dp1Yah 'fam versus new' q = 1.333 and P = 0.349, Tg(Dyr1a) q = 1.732 and P = 0.225; recognition index, one sample t-test mean versus 50%: Dp1Yah P = 0.253, Tg(Dyrk1a) P = 497] but the double transgenic mice Dp1Yah/Tg(Dyrk1a) were able, similarly to wt littermates, to discriminate the familiar versus novel objects [two ways ANOVA, variables 'genotype' and 'objects': F(3, 70) = 7.09 with P < 0.001, post hoc Tukey test: wt 'fam versus new' q = 4.543 and P = 0.002, Dp1Yah/Tg(Dyr1a) q = 5.289 and P < 0.001; recognition index, one sample t-test: wt P = 0.048, Dp1Yah/Tg(Dyrk1a) P = 0.011], suggesting that the effects of Dyrk1a overexpression are compensated by three copies of the Abcg1-Cbs region.
Lastly, we checked the learning and spatial memories using the Morris water maze task, followed by a probe test 24 h after the learning period (Fig. 5D) . Even if all the groups increased their performance to reach the platform during the learning phase, after 6 days of training (J1-J6), wt and Dp1Yah mice found the platform with lower latency than the Tg(Dyrk1a) and Dp1Yah/Tg(Dyrk1a) [two ways ANOVA variable genotype, F(3, 280) = 14.80 P < 0.001, post hoc Tukey test: wt versus Tg(Dyrk1a) q = 6.160 with P < 0.001, wt versus Dp1Yah/Tg(Dyrk1a) q = 4.752 with P = 0.004, Dp1Yah versus Tg(Dyrk1a) q = 8.103 with P < 0.001, Dp1Yah versus Dp1Yah/Tg(Dyrk1a) q = 6.641 with P < 0.001]. During the probe test, 24 h after the learning phase, controls and Dp1Yah animals were most of their time, searching in the platform quadrant (T), whereas Tg(Dyrk1a) and double transgenic mice searched randomly across the entire space [one sample ttest versus 50% mean: wt P = 0.02, Dp1Yah P = 0.05, Tg(Dyrk1a) P = 0.99 and Dp1Yah/Tg(Dyrk1a) P = 0.57]. Hence, overexpressing Cbs and Dyrk1a does not rescue the Dyrk1a dosage-dependent working and spatial memory deficits observed in the Y-maze and the Morris water maze, respectively, neither the hyperactivity observed in the open field, but rescued the object recognition impairment.
Proteomics unravels complex intermingled proteomic changes influenced by DYRK1A overexpression and by Dp1Yah trisomic genes
In order to unravel the impact of CBS and DYRK1A on cellular mechanism within the hippocampus that could lead to the memory phenotype observed in the NOR test, we profiled the proteome in the hippocampi isolated from Dp1Yah, Tg(Dyrk1a) and double [Dp1Yah, Tg(Dyrk1a)] animals and compared them with the wt control littermates. We collected the samples after the behavioural evaluation and performed a TMT labelling (Thermo Scientific, Illkirch) followed by LC-MS/MS orbitrap analysis. We were able to detect 1655 proteins of which 546 were detected in all the three genotypes with a variability below 40% (Supplementary Material, Table S4 ) and among which 338 proteins were expressed at the same level as control ones. A total of 208 proteins were found differentially expressed with levels of expression above 1.2 (206) or below 0.8 (2) in Dp1Yah, Tg(Dyrk1a) and double mutant mice (Fig. 6A) . Nine proteins were up-regulated in all three genotypes: the RIKEN cDNA 6430548 M08 gene product (6430548M08RIK), actinrelated protein 2/3 complex, subunit 1A (ARPC1A), bridging Integrator 1 (BIN1), the family with sequence similarity 213, member A (Fam213a), glyoxalase 1 (GLO1), importin 5 (LPO5), NADH dehydrogenase (ubiquinone) Fe-S protein 1 (NDUFS1), prostaglandin reductase 2 (PTGR2) and SNAP25. ToppCluster analysis of the protein content unraveled a general common network with interacting proteins modified by the three genetic conditions (Fig. 6B-C) . Functional analysis using gene ontology highlighted several cellular components affected in the three genotypes including synaptic particles, neuron projection, presynapse/synapse, axon, myelin sheath and different types of vesicles (Supplementary Material, Table S5 ). Cell/neuron projection development, morphogenesis and differentiation, as well as secretion, synaptic and anterograde trans-synaptic signalling were affected in Dp1Yah while aldehyde catabolic processes and regulation of anatomical structure size were modified in Tg(Dyrk1a). Interestingly, all these biological processes were not disturbed in double transgenic animals. Likewise, molecular functions controlling ubiquitin protein ligase, calcium ion binding and dicarboxylic acid transmembrane transporter activity deregulated in Dp1Yah or cytoskeletal protein and myosin binding perturbed in Tg(Dyrk1a) were restored [Dp1Yah, Tg(Dyrk1a)]. On the contrary, oxidoreductase activity was newly modified in the double transgenic hippocampi.
We selected three proteins with different proteomic profiles in hippocampi and studied their expression in another brain region, the cerebral cortex, using western blot analysis: the SNCA and the FUS proteins, which are associated with neurodegenerative disease (59) (60) (61) (62) and the SNAP25, a component of the SNARE complex involved in calcium-triggered exocytosis (63) (64) (65) . As shown in Figure 5D , levels of SNCA were similar to wt level. We did observe the increased amount of this protein in 
Discussion
In this report, we demonstrated that the genetic overdosage of Cbs is necessary and sufficient to induce defective NOR in three different types of DS models. CBS overdosage is certainly the main driver of the learning and memory phenotypes detected previously in DS models for the Mmu17 region (21,22) but we cannot rule out the possibility that one or more another gene(s) contribute, with Cbs, to the phenotype. Previous analysis of CBS overdosage with the same transgenic line Tg(CBS) on the FVB/N genetic background showed no change in fear-learning task and locomotor activity but increased LTP-dependent synaptic plasticity (66); a phenomenon also detected in vitro and in vivo in other DS models in which Cbs is trisomic in the C57BL/6J genetic background (21, 22) . Nevertheless, no positive effect on cognition is associated with increase in CBS dosage as previously proposed by Régnier et al. (66) . Instead, the overdosage of CBS always impairs the hippocampal-dependent NOR test suggesting that increased synaptic plasticity found in Cbs trisomic models may alter synaptic functions. Increased synaptic plasticity could occur via increased H 2 S as it has been shown that H 2 S facilitates LTP by stimulating the post-synaptic NMDA receptors (67, 68) . Moreover, a role of H 2 S has been foreseen in calcium homeostasis regulation that is also crucial for neuronal synaptic plasticity (69) . DSF was isolated from a drug screening performed in yeast cells overexpressing CBS homolog Cys4p and looking for drugs counteracting its effect on methionine auxotrophy. Although DSF has been first identified as an inhibitor of mitochondrial ALDH (70) , it is a relatively nontoxic substance, which has been on the market for more than 40 years to support the treatment of chronic alcoholism by producing an acute sensitivity to ethanol, leading to an accumulation of acetaldehyde in blood when alcohol is ingested. As acetaldehyde is responsible for many of the unpleasant effects that follow ingestion of large quantities of alcohol ('hangover'), DSF treatment discourages the patients to sustain a regular alcohol consumption by exacerbating and accelerating its unpleasant side effects. DSF is known to have a sedative effect both in mouse and patients. It is thus possible that this side effect reduces the ability of treated wt mice to perform the object recognition test as efficiently as non-treated mice. Further studies are necessary to better understand the mode of action and identify the targets of DSF affected in this behavioural test. Our ongoing studies about the mechanism of action of DSF suggest that this molecule may not directly inhibit CBS enzymatic activity but probably rather acts on the cellular consequences of CBS overexpression. The assay used for the screening allows, in principle, the isolation of drugs acting both directly or not on CBS/Cys4. This latter point is of importance given that CBS may not be a druggable target enzyme. And indeed, at present, we do not know if DSF is acting directly or indirectly on CBS but we must assume that the function altered by CBS overdosage, whatever it is, is conserved and similarly sensitive to DSF treatment in both yeast and mouse. Of note, upon absorption, DSF is rapidly reduced to diethyldithiocarbamate (DDC), which then reacts with thiol groups. Both DSF and DDC are potent copper chelators, thereby possibly affecting the activity of copper-dependent enzymes such as monooxygenases, the Cu-Zn superoxide dismutase, amine oxidase, ADN methyltransferases, and cytochrome oxidase. As a result, DSF has been shown to affect various cellular processes such as cocaine metabolism and catecholamine synthesis and proteasome inhibition and is thus under study for multiple clinical applications that include struggle against alcohol addiction, cancer chemotherapy, treatment of copper-related disorders and anti-viral treatment for hepatitis C and human immunodeficiency virus (71) . Here, we describe a new possible clinical application of DSF in DS cognition through its effect on the consequences of CBS overexpression. CBS clearly represents a new relevant therapeutic target for improving DS cognition and DSF, as such, opens new therapeutic avenues in patients with DS.
We also demonstrated that CBS genetically interacts with Dyrk1a, a well-known therapeutic target for DS. Mutual relationships between DYRK1A and CBS have previously been reported, with decreased DYRK1A protein observed in the liver (Hamelet et al., 2009 ) and increased expression observed in the brain of Cbs +/− mice (Planque et al., 2013) , while overexpression (or under-expression) of DYRK1A induce accumulation (or reduction) of CBS expression in the liver (72) . In order to explore the genetic interactions between DYRK1A and CBS, we overexpressed Dyrk1a in the Dp1Yah context by combining the Tg(Dyrk1a) and the Dp1Yah mice. Surprisingly, this experiment restored memory that is lacking in the Dp1Yah mouse model in the object recognition task, but neither normalized the increased locomotor activity in the open field or the Y-maze nor the working and spatial memory deficits. Thus, the compensation is restricted to a specific cognitive function, recognition memory, which is defective in both TgDyrk1a and Dp1Yah models. Why this dosage effect is restricted to recognition memory remains speculative. We may hypothesize that Cbs and Dyrk1a overdosage only interact in specific regions of the adult brain involved in object discrimination explaining why the increased locomotor activity and the working and visuo-spatial phenotypes induced in Tg(Dyrk1a) animals are not affected. Alternatively, the object recognition deficit is likely to result from an impact of DYRK1A on adult brain function while the other phenotypes are the result of an impact during earlier stages of brain development. On the one hand, object recognition has been shown to require undamaged hippocampal perforant path connecting ento/perirhinal cortex with the dentate gyrus for long retention intervals (>15 min) in the rat (73) (74) (75) (76) (77) (78) . On the other hand, synaptic exchanges between the median prefrontal cortex and the hippocampus seem to be sufficient to support the processing of short-term memory such as working memory observed in the Y-maze (79, 80) and hyperactivity is associated with the prefrontal cortex, basal ganglia and cerebellum (81) (82) (83) (84) . Moreover, long-term recognition memory has been shown to appear in the rat at weaning (post-natal day 21 in the mouse) (85), a period corresponding to the end of neurogenesis and synaptogenesis in the dentate gyrus of the hippocampus, and reflecting the general observation of 'infantile amnesia' observed on long-term memory tasks but not on short-term memory ability (86) .
Our proposal goes farther than the demonstration by Zhang et al. (23) that the Hsa21 homologous region on the Mmu17 is a key determinant of cognitive deficits in DS mouse models. We showed here that CBS is a key gene for DS-related phenotypes in mice with the other homologous interval Cbr3-Fam3b located on Mmu16, encompassing Dyrk1a. We should also consider that in people with DS, both genes are trisomic and thus the recognition memory deficit observed in DS persons and in the complete T21 mouse model (87) certainly depends not only on the interplay between DYRK1A and CBS but also on interaction with other Hsa21 genes that may affect different pathways or different parts of the brain.
The molecular mechanisms involved in Cbs-Dyrk1a genetic interaction have been investigated through a quantitative proteomic approach. Although limited due to the complexity of the hippocampus, the results highlight protein network interactions between the two trisomic regions. A total of 208 proteins were found deregulated, corresponding to 148 GO categories and pathways, with 72 specific to Dp1Yah (out of 121) and 9 to Dyrk1a transgenic model (out of 32, Supplementary Material, Table S5 ) and 5 shared between Dp1Yah and Tg(Dyrk1a). More interestingly, GO terms such as cortical cytoskeleton or cytoskeletal protein binding were respectively affected in Dp1Yah and in the Tg(Dyrk1a) but were restored in the double transgenic animals, uncovering somehow the nature of the pathways controlled by the epistatic interaction between CBS and DYRK1A overdosage. DYRK1A is mainly found associated with the actin cytoskeleton modulation (88) . CBS is the major enzyme involved in H 2 S production in the central nervous system (67) . Interestingly, an increase of H 2 S activates RAC1 leading to the rearrangement of the actin cytoskeleton during endothelial cell migration (89) . Thus, a simple hypothesis would be that the overdosage of CBS may lead to increased H 2 S production and further activation of RAC1 with effect on actin cytoskeleton rearrangement, a key mechanism involved in synaptic transmission. Remarkably, DYRK1A interacts with p120-catenin-Kaiso and can then modulate Rac1 (90) . Thus, one working hypothesis is based on CBS and DYRK1A pathways connected through RAC1.
DYRK1A is the main driver of defects in DS mouse models for the homologous region to Hsa21 located on Mmu16 (55) . Based on a previous study performed in DS models for the Mmu16 homologous region (91), DYRK1A has been selected as a drug target. As reported previously, treatment with epigallocatechin-3-gallate, an inhibitor of DYRK1A kinase activity, can restore some cognitive aspects found altered in people with DS but the gain was limited (16, 17) . Nevertheless, our results, by adding CBS to the limited number of DS therapeutic targets, may improve the efficiency of DS treatment, in particular by combining multiple therapies to improve the life of DS patients. Finally, an important point to emphasize is that, for DYRK1A as well as for CBS, both loss-of-function mutations and overdosage lead to intellectual deficiencies. This is important to keep in mind when considering a pharmacological intervention that aims at inhibiting one or the other, or both, of these enzymes. Therefore, drug treatment that leads to only a mild inhibition of CBS and/or DYRK1A should be favoured.
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